Search
Search Results
##search.searchResults.foundPlural##
-
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1724PDF: 1279HTML: 413 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3413PDF: 1388HTML: 2708 -
Coronavirus disease 2019 (COVID-19) severity in patients with thalassemias: A Nationwide Iranian Experience Coronavirus in patients with thalassemias
1436PDF: 503HTML: 190 -
INCREASE IN CANDIDA PARAPSILOSIS CANDIDEMIA IN CANCER PATIENTS
1817PDF: 1096HTML: 277 -
Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large b-cell lymphoma.
3507PDF: 1067HTML: 1020Figure 1: 192 -
CLINICAL AND LABORATORY FEATURES OF SICKLE CELL DISEASE S/D PUNJAB: IMPACT OF HBF AND HYDROXYUREA SCD S/D Punjab
1362PDF: 1175HTML: 127 -
-
-
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2395PDF: 1682HTML: 354 -
TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.
1932PDF: 798HTML: 550 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
850PDF: 432HTML: 309 -
CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY
2927PDF: 1128HTML: 3049 -
Bilateral Pleural Effusions due to Pulmonary Amyloidosis as the Presenting Manifestation of Multiple Myeloma
1376PDF: 779HTML: 4399Figure 1: 172Untitled: 147Untitled: 200 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1421PDF: 877HTML: 181 -
ASSESSMENT OF CONGENITAL NEUTROPENIA IN CHILDREN: COMMON CLINICAL SCENERIES AND CLUES FOR MANAGEMENT Assessment of congenital neutropenia in children
2382PDF: 1196HTML: 802 -
Severe autoimmune hemolytic anemia in Covid-19 infection Autoimmune hemolytic anemia in Covid-19
3313PDF: 1602HTML: 273 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1301PDF: 1046HTML: 298 -
THE PROTHROMBOTIC STATE ASSOCIATED WITH SARS-COV-2 INFECTION: PATHOPHYSIOLOGICAL ASPECTS COVID and Thrombosis
2099PDF: 831HTML: 315 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4511PDF: 1752HTML: 1112 -
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3309PDF: 1483HTML: 5960Fig1-Ag-Pil: 244Ag-Pil Fig.2: 245 -
THE SYSTEMIC MASTOCYTOSIS: RADIOLOGICAL POINT OF VIEW Systemic mastocytosis
1566PDF: 567HTML: 804 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2167PDF: 1564HTML: 580 -
THE BIOLOGY OF MYCOBACTERIUM TUBERCULOSIS INFECTION.
10764PDF: 6465HTML: 21861 -
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
1001PDF: 1234HTML: 118 -
PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries
1320PDF: 914HTML: 331







